The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin
Abstract
Thirty-two healthy volunteers with different SLCO1B1 genotypes ingested a 20 mg dose of atorvastatin and 10 mg dose of rosuvastatin with a washout period of 1 week. Subjects with the SLCO1B1 c.521CC genotype (n=4) had a 144% (P<0.001) or 61% (P=0.049) greater mean area under the plasma atorvastatin concentration-time curve from 0 to 48 h (AUC(0-48 h)) than those with the c.521TT (n=16) or c.521TC (n=12) genotype, respectively. The AUC(0-48 h) of 2-hydroxyatorvastatin was 100% greater in subjects with the c.521CC genotype than in those with the c.521TT genotype (P=0.018). Rosuvastatin AUC(0-48 h) and peak plasma concentration (Cmax) were 65% (P=0.002) and 79% (P=0.003) higher in subjects with the c.521CC genotype than in those with the c.521TT genotype. These results indicate that, unexpectedly, SLCO1B1 polymorphism has a larger effect on the AUC of atorvastatin than on the more hydrophilic rosuvastatin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859
Self-citationPharmacokinetic Interactions with Rifampicin: Clinical Relevance
Niemi, M., Backman, J. T., Fromm, M. F., Neuvonen, P. J., & Kivist??, K. T. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342090-00003 · Cited by 764
Self-citationA Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2)
Hsiang, B., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V., Yang, W.-P., & Kirchgessner, T. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37161 · Cited by 641
Tirona, R. G., Leake, B. F., Merino, G., & Kim, R. B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103792200 · Cited by 626
Clinical Pharmacokinetics of Atorvastatin
Lennern??s, H. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342130-00005 · Cited by 623
Ho, R. H., Tirona, R. G., Leake, B. F., Glaeser, H., Lee, W., Lemke, C. J., Wang, Y., & Kim, R. B. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.034 · Cited by 611
Nishizato, Y. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00060-2 · Cited by 511
Transporters and drug therapy: Implications for drug disposition and disease
HO, R., & KIM, R. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.05.011 · Cited by 502
LEE, E., RYAN, S., BIRMINGHAM, B., ZALIKOWSKI, J., MARCH, R., AMBROSE, H., MOORE, R., LEE, C., CHEN, Y., & SCHNECK, D. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.013 · Cited by 480
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
Pasanen, M. K., Neuvonen, M., Neuvonen, P. J., & Niemi, M. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230416.82349.90 · Cited by 470
Self-citationContribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans
Hirano, M., Maeda, K., Shitara, Y., & Sugiyama, Y. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068056 · Cited by 443
Niemi, M., Schaeffeler, E., Lang, T., Fromm, M. F., Neuvonen, M., Kyrklund, C., Backman, J. T., Kerb, R., Schwab, M., Neuvonen, P. J., et al. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114750.08559.32 · Cited by 418
Self-citationKobayashi, D., Nozawa, T., Imai, K., Nezu, J.-I., Tsuji, A., & Tamai, I. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.051300 · Cited by 416
McTaggart, F., Buckett, L., Davidson, R., Holdgate, G., McCormick, A., Schneck, D., Smith, G., & Warwick, M. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01454-0 · Cited by 413
SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid
Tornio, A., Vakkilainen, J., Neuvonen, M., Backman, J. T., Neuvonen, P. J., & Niemi, M. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000148 · Cited by 409
Self-citationKameyama, Y., Yamashita, K., Kobayashi, K., Hosokawa, M., & Chiba, K. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000170913.73780.5f · Cited by 379
Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver
Vavricka, S. R., Van Montfoort, J., Ha, H. R., Meier, P. J., & Fattinger, K. (2002) · Hepatology · doi:10.1053/jhep.2002.34133 · Cited by 373
NIEMI, M., BACKMAN, J., KAJOSAARI, L., LEATHART, J., NEUVONEN, M., DALY, A., EICHELBAUM, M., KIVISTO, K., & NEUVONEN, P. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.01.018 · Cited by 360
Self-citationGlucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization
Prueksaritanont, T., Subramanian, R., Fang, X., Ma, B., Qiu, Y., Lin, J. H., Pearson, P. G., & Baillie, T. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.5.505 · Cited by 344
Shitara, Y., Itoh, T., Sato, H., Li, A. P., & Sugiyama, Y. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041921 · Cited by 340
SIMONSON, S. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.03.010 · Cited by 330
Lau, Y. Y., Huang, Y., Frassetto, L., & Benet, L. Z. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100038 · Cited by 327
Jigorel, E., Le Vee, M., Boursier-Neyret, C., Parmentier, Y., & Fardel, O. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.010033 · Cited by 315
Effect of itraconazole on the pharmacokinetics of atorvastatin*
Kantola, T., Kivistö, K. T., & Neuvonen, P. J. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90023-6 · Cited by 300
Self-citationEvidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics
Mwinyi, J. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.016 · Cited by 293
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin
Schneck, D. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.014 · Cited by 292
Hebert, M. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00043-4 · Cited by 288
Metabolism, Excretion, and Pharmacokinetics of Rosuvastatin in Healthy Adult Male Volunteers
Martin, P. D., Warwick, M. J., Dane, A. L., Hill, S. J., Giles, P. B., Phillips, P. J., & Lenz, E. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80336-3 · Cited by 286
Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin
Hirano, M., Maeda, K., Matsushima, S., Nozaki, Y., Kusuhara, H., & Sugiyama, Y. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.014019 · Cited by 256
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin
NIEMI, M., PASANEN, M., & NEUVONEN, P. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.06.010 · Cited by 250
Self-citationGrapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin
LILJA, J., KIVISTO, K., & NEUVONEN, P. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)90048-6 · Cited by 241
Self-citationJacobsen, W., Kuhn, B., Soldner, A., Kirchner, G., Sewing, K.-F., Kollman, P. A., Benet, L. Z., & Christians, U. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15086-6 · Cited by 236
GRUBE, M., KOCK, K., OSWALD, S., DRABER, K., MEISSNER, K., ECKEL, L., BOHM, M., FELIX, S., VOGELGESANG, S., & JEDLITSCHKY, G. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.010 · Cited by 215
Cyclosporine markedly raises the plasma concentrations of repaglinide
KAJOSAARI, L., NIEMI, M., NEUVONEN, M., LAITILA, J., NEUVONEN, P., & BACKMAN, J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.07.005 · Cited by 207
Self-citationHuman Hepatobiliary Transport of Organic Anions Analyzed by Quadruple-Transfected Cells
Kopplow, K., Letschert, K., König, J., Walter, B., & Keppler, D. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.014605 · Cited by 197
Lipid-lowering response to statins is affected by CYP3A5 polymorphism
Kivistö, K. T., Niemi, M., Schaeffeler, E., Pitkälä, K., Tilvis, R., Fromm, M. F., Schwab, M., Eichelbaum, M., & Strandberg, T. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114762.78957.a5 · Cited by 193
Self-citationWu, X., Whitfield, L. R., & Stewart, B. H. (2000) · Pharmaceutical Research · doi:10.1023/a:1007525616017 · Cited by 189
Prueksaritanont, T., Ma, B., & Yu, N. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01833.x · Cited by 180
Effect of () variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers
CHUNG, J., CHO, J., YU, K., KIM, J., OH, D., JUNG, H., LIM, K., MOON, K., SHIN, S., & JANG, I. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.07.003 · Cited by 170
Backman, J. T., Luurila, H., Neuvonen, M., & Neuvonen, P. J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.04.007 · Cited by 156
Self-citationTachibana-Iimori, R., Tabara, Y., Kusuhara, H., Kohara, K., Kawamoto, R., Nakura, J., Tokunaga, K., Kondo, I., Sugiyama, Y., & Miki, T. (2004) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.19.375 · Cited by 153
HERMANN, M., Bogsrud, M. P., Molden, E., Åsberg, A., Mohebi, B. U., Ose, L., & Retterstøl, K. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.02.014 · Cited by 145
Jemal, M., Ouyang, Z., Chen, B., & Teitz, D. S. (1999) · Rapid Communications in Mass Spectrometry · Cited by 139
Kearney, A. S., Crawford, L. F., Mehta, S. C., & Radebaugh, G. W. (1993) · Pharmaceutical Research · doi:10.1023/a:1018923325359 · Cited by 131
Niemi, M., Neuvonen, P. J., Hofmann, U., Backman, J. T., Schwab, M. G., Lütjohann, D., von Bergmann, K., Eichelbaum, M. F., & Kivistö, K. T. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200505000-00005 · Cited by 125
Self-citationPasanen, M. K., Backman, J. T., Neuvonen, P. J., & Niemi, M. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0123-1 · Cited by 119
Self-citationEffect of itraconazole on the pharmacokinetics of rosuvastatin
Cooper, K. D. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(02)17633-8 · Cited by 115
Igel, M., ARNOLD, K., Niemi, M., Hofmann, U., Schwab, M. G., Lütjohann, D., VONBERGMANN, K., Eichelbaum, M. F., & Kivistö, K. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.01.010 · Cited by 108
Self-citationHermann, M., Christensen, H., & Reubsaet, L. (2005) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-005-3266-5 · Cited by 106
Ishigami, M., Honda, T., Takasaki, W., Ikeda, T., Komai, T., Ito, K., & Sugiyama, Y. (2001) · PubMed · Cited by 84
Hermann, M., Åsberg, A., Christensen, H., Holdaas, H., Hartmann, A., & Reubsaet, L. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.07.008 · Cited by 69
Kim, R. W. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.01.004 · Cited by 55
OATP-C(OATP01B1)*15 is associated with statin-induced myopathy in hypercholesterolemic patients
Morimoto, K., Ueda, S., Seki, N., IGAWA, Y., KAMEYAMA, Y., Shimizu, A., Oishi, T., Hosokawa, M., Iesato, K., & Mori, S. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.11.081 · Cited by 25
Cited by
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Self-citationGodoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Impact of OATP transporters on pharmacokinetics
Kalliokoski, A., & Niemi, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00430.x · Cited by 995
Self-citationNiemi, M., Pasanen, M. K., & Neuvonen, P. J. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002857 · Cited by 633
Self-citationRosuvastatin for Sepsis-Associated Acute Respiratory Distress Syndrome
The National Heart, L. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401520 · Cited by 537
Metadata
- Authors
- Pasanen, M. K., Fredrikson, H., Neuvonen, P. J., & Niemi, M.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2007-05-02
- Volume
- 82
- Issue
- 6
- Pages
- 726-733
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2152218609
- Cited by
- 432
- References
- 54
- FWCI
- 19.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.